npj Vaccines (Dec 2021)

SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses

  • Joshua M. Carmen,
  • Shikha Shrivastava,
  • Zhongyan Lu,
  • Alexander Anderson,
  • Elaine B. Morrison,
  • Rajeshwer S. Sankhala,
  • Wei-Hung Chen,
  • William C. Chang,
  • Jessica S. Bolton,
  • Gary R. Matyas,
  • Nelson L. Michael,
  • M. Gordon Joyce,
  • Kayvon Modjarrad,
  • Jeffrey R. Currier,
  • Elke Bergmann-Leitner,
  • Allison M. W. Malloy,
  • Mangala Rao

DOI
https://doi.org/10.1038/s41541-021-00414-4
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 18

Abstract

Read online

Abstract The emergence of variants of concern, some with reduced susceptibility to COVID-19 vaccines underscores consideration for the understanding of vaccine design that optimizes induction of effective cellular and humoral immune responses. We assessed a SARS-CoV-2 spike-ferritin nanoparticle (SpFN) immunogen paired with two distinct adjuvants, Alhydrogel® or Army Liposome Formulation containing QS-21 (ALFQ) for unique vaccine evoked immune signatures. Recruitment of highly activated multifaceted antigen-presenting cells to the lymph nodes of SpFN+ALFQ vaccinated mice was associated with an increased frequency of polyfunctional spike-specific memory CD4+ T cells and Kb spike-(539–546)-specific long-lived memory CD8+ T cells with effective cytolytic function and distribution to the lungs. The presence of this epitope in SARS-CoV, suggests that generation of cross-reactive T cells may be induced against other coronavirus strains. Our study reveals that a nanoparticle vaccine, combined with a potent adjuvant that effectively engages innate immune cells, enhances SARS-CoV-2-specific durable adaptive immune T cell responses.